Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
24 hedge funds and large institutions have $904K invested in Iterum Therapeutics in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 8 closing their positions.
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
3.1% less ownership
Funds ownership: 5.97% → 2.87% (-3.1%)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
62% less capital invested
Capital invested by funds: $2.38M → $904K (-$1.47M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$78.4K |
| 2 |
GWP
Gen-Wealth Partners
Zeeland,
Michigan
|
+$64.3K |
| 3 |
VF
Virtu Financial
New York
|
+$36.9K |
| 4 |
KF
Krilogy Financial
St. Louis,
Missouri
|
+$31.3K |
| 5 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$23.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$429K |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
-$343K |
| 3 |
Renaissance Technologies
New York
|
-$306K |
| 4 |
CFD
Creative Financial Designs
Kokomo,
Indiana
|
-$75.7K |
| 5 |
Jane Street
New York
|
-$61.4K |
ITRM Hedge Fund Activity: Q3 2025 in Review
24 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q3 2025, worth a combined $904K — down 62% from $2.38M a quarter earlier.
Fund positioning in ITRM was balanced in Q3 2025: 8 funds opened new positions, 8 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was CAPTRUST Financial Advisors, adding an estimated $78.4K. The largest seller was Sabby Management, exiting entirely with an estimated $429K sold.
- 24 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $904K of Iterum Therapeutics stock for Q3 2025, down 62% quarter-over-quarter.
- 8 funds opened new Iterum Therapeutics positions in Q3 2025 and 8 closed out, a net change of 0 holders.
- The largest Iterum Therapeutics buyer in Q3 2025 was CAPTRUST Financial Advisors, an estimated $78.4K added.
- The largest Iterum Therapeutics seller in Q3 2025 was Sabby Management, an estimated $429K sold.
Based on aggregated 13F filings for Q3 2025.